Lupin starts strategic review of Japanese arm, targets higher-growth areas

Lupin has started a strategic review of its Japanese operations, people with knowledge of the matter said, as the Indian pharmaceutical company seeks to focus on higher-growth areas.
 

The Mumbai-based drugmaker is working with advisers as it explores options for the Japan business, according to the people,
who asked not to be identified because the information is private.
 

Japanese subsidiaries of Lupin produce treatments in therapeutic areas, including psychiatry and neurology. Its business in the country, which generated 35.5 billion yen ($314 million) of revenue in the latest financial year, is the sixth-largest generic drugmaker in Japan, Lupin’s website shows.